Prediction of Early Breast Cancer Metastasis from DNA Microarray Data Using High-Dimensional Cox Regression Models

Christophe Zemmour, François Bertucci, Pascal Finetti, Bernard Chetrit, Daniel Birnbaum, Thomas Filleron, Jean-Marie Boher

To cite this version:
Christophe Zemmour, François Bertucci, Pascal Finetti, Bernard Chetrit, Daniel Birnbaum, et al.. Prediction of Early Breast Cancer Metastasis from DNA Microarray Data Using High-Dimensional Cox Regression Models. Cancer Informatics, 2015, 14(Suppl 2), pp.129-138. 10.4137/cin.s17284. inserm-01996812

HAL Id: inserm-01996812
https://inserm.hal.science/inserm-01996812
Submitted on 28 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Introduction

DNA microarray studies identified gene expression signatures predictive of metastatic relapse in patients with early breast cancer.\(^1\)\(^-\)\(^3\) Full validation of such signatures across independent studies needs to overcome difficulties inherent to the use of many methodological differences concerning the methods for measuring mRNA expression levels, the microarray platforms, the data processing, and analysis methods used to predict the study outcome and classify the patients into low- and high-risk categories.\(^4\)

In the first major studies published, the authors reduced the set of predictive genes by applying a simple univariate feature selection. For example, van’t Veer et al successfully predicted the 5-year metastatic status in a population of lymph...
node-negative breast cancer patients by first ranking each candidate gene according to the magnitude of its correlation coefficient with the study outcome observed in a training set of 78 randomly selected patients. The list of the 70 most-correlated genes (hereafter called the Amsterdam 70-gene signature) was identified using a leave-one-out cross-validation procedure as the optimal gene set that best predicted the 5-year status of metastatic disease. The resulting prognostic classification was based on the correlation coefficients of the top-ranked 70 genes with the average good-prognosis profile established using the expression profile of the optimal gene set among the patients free of metastatic relapse at 5 years in the training set. For this purpose, patients were then assigned to good-prognosis (low risk) and poor-prognosis (high risk) groups according to an optimized sensitivity threshold resulting in misclassification of not more than 10% of the poor-prognosis group in the training set. The good performance of this 70-gene classifier was first verified in an independent validation set of 19 patients with lymph node-negative breast cancer, then in an independent series of 295 (including 61 from the original training set) consecutive patients with lymph node-negative disease and lymph node-positive disease. Later, in 2005, Wang et al identified from a training set of 115 tumors a 76-gene signature predictive of the development of distant metastasis in patients with lymph node-negative breast cancer. Similar to van’t Veer et al, a bootstrap univariate Cox regression feature selection procedure was conducted for determining the list of genes ranked according to their association with the metastasis-free survival (MFS). The individual relapse scores were first derived by summing individual expressions of candidate genes weighted by their corresponding standardized Cox’s regression coefficients. A list of 76 genes was selected as the optimal gene set by adding sequentially the top-ranked genes until a maximum AUC (area under the curve) was reached, of whom 60 genes related to estrogen receptor (ER)-positive patients and 16 genes to ER-negative patients. The threshold relapse score was determined from the ROC (receiver operating characteristic) curve of the training set to ensure 100% sensitivity and the highest specificity. The prognostic value of this 76-gene signature was validated in an independent set of 171 patients with lymph node-negative disease. Like the 70-gene signature, this signature was a strong predictor of the metastatic risk even when corrected for traditional prognostic factors in multivariable analysis and a highly informative tool in predicting patients with early distant metastases. Despite very similar prognostic performances, these 70-gene and 76-gene signatures showed a small gene overlap with only three genes in common.

Here, we propose to study the performance of three high-dimensional Cox regression models for determining the list of outcome predictive genes and the rules for prognostic classification: the LASSO (Least Absolute Shrinkage and Selection Operator), CoxBoost, and Elastic net methods. As opposed to standard multivariable regression analysis, these selection methods handle high-dimensional regression variables with no prior feature selection step by shrinking all the regression coefficients toward zero, and thus forcing many regression variables to be exactly zero. Such shrinkage and stepwise regression methods have been shown by many authors to outperform the simple dimension reduction methods for survival prediction from microarray data. To our knowledge, the accuracy and predictive performances in independent validation sets of classifiers derived from high-dimensional Cox regression models have been less studied.

In this article, we have used a systematic approach for training an entire classifier based on three such modeling strategies on the well-known original van’t Veer dataset. The selection of predictive genes and the rules associated with the prognostic classifier were developed in the training set selected by van’t Veer et al, thus allowing a direct comparison with the well-established Amsterdam 70-gene signature yet used in clinical routine in several countries. The internal van’t Veer’s validation dataset and two external validation sets (van de Vijver’s and Desmedt’s datasets) were used to evaluate the diagnostic accuracy, the predictive performances, and the classifier transferability into clinic.

Materials and Methods

Breast cancer datasets. We downloaded three retrospective datasets of node-negative early breast cancer samples profiled using oligonucleotide microarrays (Supplementary Table 1). Gene expression and histoclinical data were retrieved from National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) database and authors’ websites. Only samples from women with all the following annotations available were selected for the present study: patients’ age, pathological tumor size and grade, ER and V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) statutes, and follow-up.

The van’t Veer’s dataset included 97 patients (78 in the training set and 19 in the validation set), 46 of whom developed distant metastasis within 5 years. The van de Vijver’s dataset included 151 patients (61 of whom were also in the van’t Veer’s study), 40 of whom developed distant metastasis within 5 years. The Desmedt’s dataset included 197 patients, 13 of whom developed distant metastasis within 5 years. The three datasets included a total of 384 unique pretreatment samples, whose histoclinical characteristics are summarized in Table 1.

Gene expression data processing. The three datasets used two different oligonucleotide-based technological platforms (Agilent and Affymetrix). Before analysis, data were processed. First, we mapped hybridization probes. Agilent probes annotations were retrieved and updated using both SOURCE (http://smd.stanford.edu/cgi-bin/source/source-Search) and EntrezGene (Homo sapiens gene information db, release from 09/12/2008, ftp://ftp.ncbi.nlm.nih.gov/gene/), whereas Affymetrix annotations were updated using NetAffx Annotation files (www'affymetrix.com; release from
Table 1. Clinical characteristics in the three breast cancer datasets.

| CLINICAL CHARACTERISTICS          | VAN’T VEEER’S DATASET (n = 97) | VAN DE VIJVER’S DATASET (n = 151) | DESMEDT’S DATASET (n = 197) |
|-----------------------------------|---------------------------------|-----------------------------------|-----------------------------|
| Patient’s age                     | ≥40 years 74 (76%)              | 115 (76%)                         | 161 (82%)                   |
|                                   | <40 years 23 (24%)              | 36 (24%)                          | 36 (18%)                    |
| Pathological tumor size           | <20 mm 44 (45%)                 | 82 (54%)                          | 101 (51%)                   |
|                                   | ≥20 mm 53 (55%)                 | 69 (46%)                          | 96 (49%)                    |
| Pathological grade                | 1–2 37 (38%)                    | 80 (53%)                          | 114 (58%)                   |
|                                   | 3 60 (62%)                      | 71 (47%)                          | 83 (42%)                    |
| ER status                         | Positive 72 (74%)               | 110 (73%)                         | 136 (69%)                   |
|                                   | Negative 25 (26%)               | 41 (27%)                          | 61 (31%)                    |
| HER2 status                       | Negative 82 (84%)               | 125 (83%)                         | 186 (94%)                   |
|                                   | Positive 15 (16%)               | 26 (17%)                          | 11 (6%)                     |
| Metastatic relapse within 5 years | Yes 46 (47%)                    | 40 (27%)                          | 36 (18%)                    |
|                                   | No 51 (53%)                     | 111 (73%)                         | 161 (82%)                   |

01/12/2008). All probes were then mapped based on their EntrezGeneID. When multiple probes represented the same GeneID, the one with the highest variance was selected to represent the GeneID in the corresponding dataset.

Second, each dataset was normalized separately. For the two Agilent sets, we applied quantile normalization to available processed data. For the Affymetrix set, we applied robust multichip average (RMA) to the raw data with the non-parametric quantile algorithm as normalization parameter. Quantile normalization and RMA were done in R using Bioconductor and associated packages. As the dataset used for training the models was the van’t Veer’s one, we also proceeded with these data, as the authors, to a final selection of the probes significantly regulated, namely, with at least a two-fold difference in more than five tumors. After these processing steps, data were analyzed. To avoid biases related to immunohistochemistry (IHC) across different institutions and to increase the amount of informative data, the expression statutes (negative/positive) of ER, progesterone receptor (PR), and ERBB2 were defined using mRNA expression data of ESR1, PGR, and ERBB2 genes, respectively, as previously described.

Genomic prognostic classifier selection using high-dimensional Cox models. High-dimensional Cox regression models. The CoxBoost algorithm is a stepwise selection method, which starts from the null model and updates the estimate of only one regression coefficient at each step, the one that most improves a first-order approximation of a penalized log-partial likelihood of a Cox model, under a defined condition of shrinkage. Once selected, the estimators remain in the model and the dimension is incremented by one at each step. The iterative nature of the boosting method allows to stop the process at the step in which the model better explains the data while accounting for the potential correlations between variables, retaining only the most relevant predictors, whereas setting the others to zero.

Both LASSO and Elastic net methods shrink the estimates of the regression coefficients toward zero relative to the maximum likelihood estimates by maximizing a penalized log-partial likelihood function using penalty functions. Applying L1 penalty, the LASSO method tends to select a few set of predictive genes with little shrinkage, whereas Elastic net, by weighting L1 and L2 penalty functions, tends to set fewer regression coefficients to be exactly zero and to apply more shrinkage to the remaining coefficients.

Choice of tuning parameters. To ensure the comparability between different methods, we used an automatic selection procedure to set the parameters and to determine the number of predictive genes to be included in each model. The gene expression levels were treated as continuous values in these models.

For the CoxBoost model, we used the cross-validation routine optimCoxBoostPenalty implemented in the package CoxBoost for R version 1.4 to first determine the optimal penalty (amount of shrinkage), with a k-fold equal to 5. Once this parameter was determined, the other tuning parameter of the algorithm, namely, the number of boosting steps to perform, was selected via the function cv.CoxBoost, with also a k-fold equal to 5. The dimension of the selected multivariate Cox model was finally set by the principal routine CoxBoost.

For the LASSO and Elastic net methods, the regularization parameter $\lambda$ was chosen via the cross-validation routine cv.glmnet before running the main algorithm implemented in the R package glmnet version 1.9–8, with a k-fold equal to 5. The other tuning parameter of the Elastic net method, the mixing parameter $\alpha$, which determines the balance between the L1 and L2 penalties, was set to a default value of 0.5 in order to have a more flexible alternative to the LASSO procedure.

Prognosis prediction. For each selected multivariate model, a classifier predicting the risk of metastatic relapse was based...
on the linear predictor given by the model. Following van’t Veer et al., the threshold for discriminating between predicted poor prognosis vs. good prognosis was determined as the sensitivity threshold (defined as the proportion of actual poor-prognosis patients assigned to the predicted poor-prognosis class) resulting in misclassification of no more than 10% of the poor-prognosis group in the training set.

In the first step, each method was applied and the models were trained in the original van’t Veer’s training set of 78 patients,34 of whom showed metastatic relapse within 5 years. In the second phase, the methodology was repeated in the same training set of 78 patients, but applied only to the 10,002 genes shared by the van’t Veer’s, van de Vijver’s, and Desmedt’s genomics platforms to make possible the application of defined multigene predictors in their entirety on the two latter datasets for testing their robustness.

**Strategy for assessing and comparing performances of the prognostic classifiers.** The clinical endpoint was the MFS, defined as the duration from the date of diagnosis of breast cancer to the date of metastatic relapse and censored after 5 years of follow-up. The predictive ability and the robustness of the classifiers were first assessed on the original van’t Veer’s validation set (19 patients). We will refer to this validation as internal validation. In the second step, they were evaluated in the independent van de Vijver’s and Desmedt’s datasets.2,13 We will refer to this validation step as external validation. The sample classifications based on the 70-gene signature were retrieved for the three datasets in their respective original publications and served as a benchmark classification of tumor samples.

**Prognostic evaluation criteria.** The main evaluation criteria of each classifier, including the 70-gene signature, in each validation set were its sensitivity, specificity, and accuracy in terms of prediction of metastatic relapse at 5 years. The sensitivity was defined as the proportion of actual relapses within 5 years attributed to the poor-prognosis class. The specificity was defined as the proportion of patients remaining relapse-free at 5 years attributed to the good-prognosis class. The accuracy was defined as the proportion of patients attributed to the prognostic class corresponding well to their actual status.

Other prognostic evaluation criteria were the hazard ratios (HRs) for metastatic relapse in the predicted poor-prognosis class vs. good-prognosis class, unadjusted and adjusted for the classical prognostic histoclinical variables. The latter were dichotomized as follows: thresholds were 40 years for the patients’ age and 20 mm for the pathological tumor size, whereas the pathological grade was treated as ≤2 vs. 3 and the ER and Human Epidermal Growth Factor Receptor-2 (HER2) statuses as negative vs. positive. Survivals were calculated using the Kaplan–Meier method, and curves were compared with the log-rank test. HRs were estimated with 5% confidence intervals using the standard Cox regression model. We also assessed the concordance of classifications based on the four models by using two-way contingency-table analyses and Fisher’s exact test.

**Biological coherence.** To explore the biological pathways linked to our classifiers in breast cancer, we applied Gene Set Enrichment Analysis (GSEA) (http://www.broadinstitute.org/gsea/) for comparing the expression profiles of predicted poor-prognosis vs. good-prognosis classes in the van de Vijver’s and Desmedt’s datasets.19 Analysis was limited to the gene ontology (GO) gene sets (list CS) from the Molecular Signatures database (http://www.broadinstitute.org/gsea/msigdb). Before analysis, each dataset was filtered to remove probes with low and poorly measured expression and standard deviation inferior to 0.25 log2 units, resulting in 11,184 and 12,712 genes, respectively. We used the signal-to-noise metric for ranking these filtered genes, weighted enrichment statistic for computing enrichment score (ES) of each gene set tested, and 1000 phenotype permutations to evaluate significance. Gene sets were retained as significant at the 5% level with a false discovery rate (FDR) under 25%.

**Results**

**Internal performances and validation of the prognostic classifiers.** CoxBoost, LASSO, and Elastic net applied to the van’t Veer’s training set (78 samples) identified prognostic models of 19, 23, and 36 genes, respectively, whose lists are nested, except for two genes of the CoxBoost model, which are not included in the two latter lists (data not shown). Each model was then applied to classify these 78 samples. As expected, the performances were excellent (Table 2): accuracy, sensitivity, and specificity of classifications were, respectively, 94, 91, and 95% for the CoxBoost model, 95, 91, and 98% for the LASSO model, and 95, 91, and 98% for the Elastic net model. For comparison, the Amsterdam 70-gene signature showed 78% accuracy, 91% sensitivity, and 68% specificity.

The predictive performance of our models was then tested in the internal validation set (n = 19 patients). The 5-year metastatic relapse was predicted by all four classifiers with two–four out of 19 incorrect classifications. The CoxBoost and Elastic net models classified the patients exactly in the same groups (79% accuracy, 75% sensitivity, and 86% specificity). The LASSO classifier showed performances (84% accuracy, 83% sensitivity, and 86% specificity) similar to those of the Amsterdam 70-gene signature (90% accuracy, 92% sensitivity, and 86% specificity) for 5-year MFS on the validation set (Table 2). The estimated HRs for metastatic relapse in the predicted poor-prognosis class as compared to the predicted good-prognosis class were 5.34 [1.39–20.44] (P = 0.007) for the CoxBoost model, 6.59 [1.41–30.91] (P = 0.007) for the LASSO model, 5.34 [1.39–20.44] (P = 0.007) for the Elastic net, and 8.93 [1.89–42.21] (P = 0.001) for the Amsterdam 70-gene signature.

**External validation and performances of the prognostic classifiers.** The same methodology was repeated in the same training set (78 samples), but limited to the 10,002 genes...
common to the genomics platforms used in the van’t Veer’s, van de Vijver’s, and Desmedt’s datasets, to define genomic predictors applicable in their entirety on the two external validation datasets. The optimal number of genes was smaller than previously, with 6, 18, and 29 genes for CoxBoost, LASSO, and Elastic net, respectively (Supplementary Table 2), but showed clear overlap with the corresponding gene lists above identified in the van’t Veer’s learning set (data not shown). These 6-, 18-, and 29-gene classifiers also showed strong overlap when compared together: the six genes included in the CoxBoost model were included in the 18 genes of the LASSO model, which were all but one included in the 29-gene Elastic net model. Each classifier was then applied to the two external validation sets separately, and its performances were tested.

**van de Vijver’s dataset.** Results of sensitivity, specificity, and accuracy in the van de Vijver’s population are shown in Table 3. CoxBoost, LASSO, and Elastic net kept good and comparable performances, while reaching until 62% in specificity for Elastic net. The CoxBoost, LASSO, and Elastic net classifiers were quite accurate (63, 64, and 66%, respectively). Particularly, the Elastic net signature was stable in terms of sensitivity. These results obtained in a larger independent validation set confirmed the robustness of our classifiers and suggested similar performances between them. HRs for metastatic relapse in the predicted poor-prognosis class as compared to the predicted good-prognosis class were 4.57 [2.1–9.95] (P < 0.001) for the CoxBoost model, 4.58 [2.18–9.66] (P < 0.001) for the LASSO model, and 4.94 [2.35–10.41] (P < 0.001) for the Elastic net model. The Amsterdam 70-gene classifier was also highly significant, with a HR equal to 7.57 [2.08–110.88] (P = 0.001). When observing the related survival curves (Fig. 1), it appeared that the CoxBoost, LASSO, and Elastic net classifiers were able to detect a large number of actual relapses regularly observed within 5 years, while misclassifying some patients with actual relapse close to the 5-year timepoint by attributing them to the predicted good-prognosis class. Models according to higher weight in this later period would be probably more accurate to predict the metastasis relapse around the 5-year perspective. This observation can be related to the fact that the classifiers are linked to proliferation functions. The CoxBoost, LASSO, and Elastic net classifiers were also highly significant in multivariate models, with HRs above 3.61 (Table 4). Particularly, they were more significant while having HRs inferior to that of the Amsterdam 70-gene signature. The low specificity of the Amsterdam signature may explain its high and more variable HRs.

**Desmedt’s dataset.** In the Desmedt’s set (Table 3), the CoxBoost, LASSO, and Elastic net classifiers had again a good sensitivity (83, 75, and 83%, respectively), while having a specificity above 50% for LASSO and Elastic net (52 and 53%, respectively). The latter classifier remained the most accurate (59%), outperforming by 14% the very sensitivity (97%) Amsterdam 70-gene signature that was 45% accurate. The univariate HRs for metastatic relapse were 4.14 [1.72–9.95] (P < 0.001) for the CoxBoost classifier, 2.96 [1.39–6.3] (P = 0.003) for the LASSO classifier, 4.95 [2.06–11.89] (P < 0.001) for the Elastic net classifier, and 15.19 [2.08–110.88] (P < 0.001) for the Amsterdam 70-gene signature. The related MFS curves (Fig. 2) had a similar pattern to their van de Vijver’s dataset counterparts, with some patients misclassified close to the 5-year timepoint. The Elastic net classifier was again more significant in the multivariate model (Table 4) than the Amsterdam 70-gene classifier (P = 0.003 and P = 0.005, respectively), while having HRs inferior but less variable. Especially, the other two classifiers (CoxBoost and LASSO) were also confirmed in a multivariate model on this external validation dataset.
Concordance of predictions and biological significance of the classifiers. We compared the concordances of predictions (prognostic classifications) based on the three models and the 70-gene signature using two-way contingency-table analyses in each external validation set. All the comparisons yielded significant correlations ($P < 0.001$, Fisher’s exact test). The concordance rates (Supplementary Table 3) between our three classifiers ranged from 87 to 94% in the van de Vijver’s samples and 76 to 92% in the Desmedt’s samples, with the Elastic net model having the highest level of correlation with the two other models in each dataset. The concordance rates between each of our classifiers and the 70-gene classifier ranged from 73 to 75% in the van de Vijver’s samples and 63 to 66% in the Desmedt’s samples.

Such high concordance rates were rather expected between our three classifiers given the strong overlap between the three gene lists (Supplementary Table 2). We also compared the genes included in our three models with the 48 unique named genes present in the 70-gene signature (Supplementary Table 4): four genes out of six (67%) of the CoxBoost classifier were included within the 48 genes (8%), six genes out of 18 (33%) of the LASSO classifier were included within the 48 genes (13%), and seven genes out of 29 (24%) of the Elastic net classifier were included within the 48 genes (15%).

No GO analysis could be applied directly to our three classifiers because of the low number of genes included. We thus applied GSEA to each classification in each external validation dataset. In all analyses, the significant ontologies were associated with genes overexpressed in the predicted poor-prognosis class and by far the most represented ones were related to cell proliferation, including for example “cell cycle phase,” “cell cycle process,” “mitotic cell cycle,” “M phase,” “interphase,” “DNA replication,” and “mitosis.” Table 5 shows the top 10 GOs. As expected given the strong gene overlap, the overlap between these three classifiers regarding the overrepresented GOs was very important (Supplementary Fig. 1). More interestingly, a similar strong overlap was observed with the GOs overrepresented with the 70-gene signature, despite a much smaller gene overlap. Clearly, these results suggested that our three classifiers were biologically relevant and associated with the same biological phenotype, mainly cell proliferation, which was higher in the predicted poor-prognosis classes.

Discussion
In their pioneered work, van’t Veer et al used microarrays to generate the transcriptional profile of 97 early breast cancers and identified a 70-gene signature predictive of the early development of distant metastasis, even when corrected for the
Table 4. Multivariate analyses for 5-year MFS in the external validation sets.

| CLASSIFIER                              | PATIENT’S AGE | SIGNATURE (PREDICTED POOR PROGNOSIS) | PATIENT’S AGE | SIGNATURE (PREDICTED POOR PROGNOSIS) | PATIENT’S AGE | SIGNATURE (PREDICTED POOR PROGNOSIS) | PATIENT’S AGE | SIGNATURE (PREDICTED POOR PROGNOSIS) | PATIENT’S AGE | SIGNATURE (PREDICTED POOR PROGNOSIS) |
|----------------------------------------|---------------|-------------------------------------|---------------|-------------------------------------|---------------|-------------------------------------|---------------|-------------------------------------|---------------|-------------------------------------|
| van de vijver’s dataset (n = 151)     | 0.23 [0.06–2.48] | 0.84 [0.49–1.49] | 0.91 [0.77–1.24] | 0.90 [0.58–1.41] | 0.88 [0.56–1.36] | 0.006 [0.001–1.9] | 1.28 [0.77–2.04] | 0.022 [0.01–0.5] | 2.22 [1.34–4.57] | 0.036 [0.019–0.69] |
| Amsterdam 70-gene                     | 1.38 [0.72–2.69] | 1.41 [0.73–2.71] | 0.90 [0.57–1.36] | 0.88 [0.55–1.40] | 0.88 [0.57–1.38] | 0.001 [0.001–1.9] | 1.86 [1.01–3.41] | 0.023 [0.01–0.5] | 3.03 [1.61–5.68] | 0.006 [0.003–1.04] |
| CoxBoost 6-gene                       | 1.56 [0.79–3.0]  | 2.14 [1.08–4.67] | 0.70 [0.42–1.19] | 0.74 [0.47–1.19] | 0.68 [0.40–1.16] | 0.001 [0.001–1.9] | 1.79 [0.91–3.4]  | 0.103 [0.05–0.20] | 3.65 [1.63–8.17] | 0.002 [0.001–0.65] |
| Lasso 18-gene                         | 1.62 [0.79–3.34] | 2.14 [1.08–4.67] | 0.70 [0.42–1.19] | 0.74 [0.47–1.19] | 0.68 [0.40–1.16] | 0.001 [0.001–1.9] | 1.79 [0.91–3.4]  | 0.103 [0.05–0.20] | 3.65 [1.63–8.17] | 0.002 [0.001–0.65] |
| elastic net 29-gene                    | 1.61 [0.76–3.33] | 2.14 [1.08–4.67] | 0.70 [0.42–1.19] | 0.74 [0.47–1.19] | 0.68 [0.40–1.16] | 0.001 [0.001–1.9] | 1.79 [0.91–3.4]  | 0.103 [0.05–0.20] | 3.65 [1.63–8.17] | 0.002 [0.001–0.65] |

**Note:** Table 4 shows the results of multivariate analyses for 5-year MFS in the external validation sets. The table includes the hazard ratios (HRs) and 95% confidence intervals (CIs) for different classifiers, such as van de vijver’s dataset, Amsterdam 70-gene, CoxBoost 6-gene, Lasso 18-gene, elastic net 29-gene, and elastic net 29-gene. The HRs indicate the risk of poor prognosis associated with the presence of certain factors, such as age, signature status, pathological tumor size, and tumor grade. The 95% CIs provide a range within which the true HR is likely to fall. The results suggest that these classifiers can predict the risk of poor prognosis accurately, with HRs ranging from 0.23 to 3.65 and 95% CIs ranging from 0.001 to 3.65. The table also shows the number of samples in each dataset, ranging from 151 to 197, which helps in understanding the sample size and the reliability of the results.
Figure 2. MFS curves for the four classifiers in the Desmedt’s external validation set. Kaplan–Meier curves are shown for the Amsterdam 70-gene signature (top left), the LASSO classifier (top right), the CoxBoost classifier (bottom left), and the Elastic net classifier (bottom right). P-values are estimated using the log-rank test.

genes for the CoxBoost, LASSO, and Elastic net methods, respectively.

The three high-dimensional Cox regression models with automatic selection of the tuning parameter by cross-validation led to the definition of prognostic signatures with similar predictive ability, added significant prognostic information to that provided by the classical parameters. With quite small sets of genes, the CoxBoost, LASSO, and Elastic net methods outperformed the Amsterdam 70-gene signature in terms of accuracy (see Table 3). The Amsterdam 70-gene signature remains the most sensitive predictor. In our opinion, our results highlight the relative poor specificity performance of the Amsterdam 70-gene signature, which tends to overestimate the proportion of patients with recurrence at 5 years. Finding a small subset of genes not only facilitates the transfer to the clinics but also limits the selection of false-positive predictive genes. With only six genes, the classifier derived from the CoxBoost model and the Amsterdam 70-gene signature had similar performance in terms of sensitivity until 4 years (93% sensitivity). This suggests that further improvements can be achieved by adapting weighted Cox regression methods to high-dimensional microarray data. Selecting genes predictive of late recurrences could likely improve the overall performance of genomic classifiers, and thus help the clinicians to better tailor adjuvant chemotherapy to their patients. Our study was designed to illustrate the attractiveness of high-dimensional Cox regression models. We used an automatic selection procedure to control the number of predictive genes to be included in each model. Even if such a procedure follows some good statistical principles, we do not fully recommend its use. More flexibility in the choice of the default parameterization may be desirable in practice because it may strongly affect the predictive performance of each method. This is also true for the determination of the cutoff value to predict the poor- and good-prognosis classes. Here, the choice to use the value resulting in a misclassification not superior to 10% of the actual poor-prognosis patients in the training set to predict the class membership was supported by the aim to select the patients who will most benefit from a chemotherapy prescription. In other situations, an overall accuracy or an AUC is a better alternative measure to assess the overall performance or predict the class membership. In a perspective to determine more accurate signatures, ensemble methods aggregating models trained on different samples may capture nonlinear relationship and ensure better transferability. Despite all these limitations, our work supports the attractiveness of high-dimensional Cox regression for...
Table 5. List of top 10 ontological terms of GO overrepresented (GSEA) for the four classifiers in the external validation sets.

| Term                          | CoxBoost 6-GENE          | LASSO 18-GENE                   | ELASTIC NET 29-GENE            | AMSTERDAM 70-GENE             |
|-------------------------------|--------------------------|--------------------------------|--------------------------------|-------------------------------|
| van de Vijver’s set           |                          |                                |                                |                               |
| Cell_Cycle_Phase              | Cell_Cycle_GO_0007049    | Cell_Cycle_Phase                | Mitotic_Cell_Cycle             |                               |
| Mitotic_Cell_Cycle            | Cell_Cycle_Process       | Cell_Cycle_Process              | Cell_Cycle_Process             |                               |
| Chromosomal_Part              | Chromosome               | Chromosome                      | Cell_Cycle_Phase               |                               |
| Chromosome                    | Chromatin                | Mitotic_Cell_Cycle              | M_Phase_Of_Mitotic_Cell_Cycle  |                               |
| Cell_Cycle_Process            | Cell_Cycle.GO_0007049    | Magnesium_Ion_Binding           | Cell_Cycle.GO_0007049          |                               |
| M_Phase                       | Chromosomal_Part         | Interphase                      | Cell_Cycle.GO_0007049          |                               |
| Cell_Cycle_GO_0007049         | Mitotic_Cell_Cycle       | Chromosomal_Part                | Mitosis                        |                               |
| Chromatin                     | M_Phase                  | M_Phase                         | M_Phase                        |                               |
| Magnesium_Ion_Binding         | M_Phase_Of_Mitotic_Cell_Cycle | Interphase_Of_Mitotic_Cell_Cycle | Chromosome                  |                               |
| DNA_Replication               | Mitosis                  | M_Phase_Of_Mitotic_Cell_Cycle  | Chromatin                      |                               |
| Desmedt’s set                 |                          |                                |                                |                               |
| Cell_Cycle_GO_0007049         | Chromosome               | Chromosome                      | Response_To_DNA_Damage_Stimulus|                               |
| Mitotic_Cell_Cycle            | Chromosomal_Part         | Chromosomal_Part                | Microtubule_Cytoskeleton       |                               |
| Cell_Cycle_Process            | Mitotic_Cell_Cycle       | Mitosis                         | DNA_Repair                     |                               |
| Regulation_Of_Mitosis         | Cell_Cycle.GO_0007049    | Mitosis                         | DNA_Repair                     |                               |
| Chromosomal_Part              | Cell_Cycle_Process       | Cell_Cycle_Process              | Chromosomal_Part               |                               |
| Cell_Cycle_PHASE              | M_Phase_Of_Mitotic_Cell_Cycle | Cell_Cycle.Process             | Cell_Division                 |                               |
| Regulation_Of_Cell_Cycle      | Mitosis                  | Cell_Cycle.GO_0007049           | M_Phase_Of_Mitotic_Cell_Cycle  |                               |
| Chromosome                    | Cell_Cycle_Phase         | Cell_Cycle.GO_0007049           | M_Phase_Of_Mitotic_Cell_Cycle  |                               |
| Mitosis                       | Chromosome_Segregation    | Cell_Cycle_Checkpoint_GO_0000075 | Cytokinesis                  |                               |
| M_Phase_Of_Mitotic_Cell_Cycle| Cell_Cycle_Checkpoint.GO_0000075 | Chromosome_Segregation         | Mitotic_Cell_Cycle            |                               |

Notes: The GO ontological terms are ordered from top to bottom by their increasing GSEA normalized enrichment score (NES). Those written in bold are common to the four classifiers.

predicting the status of breast cancer metastasis from breast DNA microarray data.

**Author Contributions**

Conceived and designed the methods: CZ, FB, PF, DB, BC, TF, JMB. Analyzed the data: CZ, FB, PF, DB, BC, TF, JMB. Provided preprocessed genomics data and cluster support for calculation: PF, FB, BC. Wrote the first draft of the manuscript: CZ, FB, PF, DB, BC, TF, JMB. Contributed to the writing of the manuscript: CZ, FB, PF, JMB. Agreed with manuscript results and conclusions: CZ, FB, PF, DB, BC, TF, JMB. Jointly developed the structure and arguments for the paper: CZ, PF, FB, JMB. Made critical revisions and approved the final version: CZ, FB, PF, DB, BC, TF, JMB. All authors reviewed and approved the final manuscript.

**Supplementary Files**

**Supplementary Table 1.** Description of the three breast cancer datasets.

**Supplementary Table 2.** Gene lists of the CoxBoost 6-gene, LASSO 18-gene and Elastic net 29-gene classifiers.

**Supplementary Table 3.** Concordant classification rates between the four classifiers in the external validation sets.

**Supplementary Table 4.** Gene overlap between the four classifiers.

**Supplementary Figure 1.** Venn diagrams showing the overlap between the GO ontological terms overrepresented (GSEA) in the four classifiers in the external validation sets. The number of significant ontologies is indicated between brackets.

**REFERENCES**

1. van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature*. 2002;415(6871):530–6.
2. Van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med*. 2002;347(25):1999–2009.
3. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. *Lancet*. 2005;365(9460):671–9.
4. Bertucci F, Finetti P, Cervera N, Maraninchi D, Viens P, Birnbaum D. Gene expression profiling and clinical outcome in breast cancer. *OMICS*. 2006;10(4):429–43.
5. Tibshirani R. The lasso method for variable selection in the Cox model. *Stat Med*. 1997;16(4):385–95.
6. Tutz G, Binder H. Generalized additive modeling with implicit variable selection by likelihood-based boosting. *Biometrics*. 2006;62(4):961–71.
7. Zou H, Hastie T. Regularization and variable selection via the elastic net. *J R Stat Soc Ser B*. 2005;67:301–20.
8. Bovelstad HM, Nygård S, Starfeldt HL, et al. Predicting survival from microarray data – a comparative study. *Bioinformatics*. 2007;23(16):2080–7.
9. De Bin R, Sauerbrei W, Boulesteix AL. Investigating the prediction ability of survival models based on both clinical and omics data: two case studies. Stat Med. 2014;33(36):5310–29.

10. Kaneko S, Hirakawa A, Hamada C. Gene selection using a high-dimensional regression model with microarrays in cancer prognostic studies. Cancer Inform. 2012;11:29–39.

11. van Wieringen W, Kun D, Hampel R, Boulesteix A. Survival prediction using gene expression data: a review and comparison. Comput Stat Data Anal. 2009;53:1590–603.

12. Waldmann P, Meszaros G, Gredler B, Fuerst C, Solkner J. Evaluation of the lasso and the elastic net in genome-wide association studies. Front Genet. 2013;4:270.

13. Desmedt C, Piette F, Loi S, et al; TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13(11):3207–14.

14. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–64.

15. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.

16. Binder H. Cox models by likelihood based boosting for a single survival endpoint or competing risks. R Package Version 1.4. 2013. Available at: http://CRAN.R-project.org/package=CoxBoost. [Ref Type: Online Source].

17. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.

18. Friedman J, Hastie T, Simon N, Tibshirani R. Lasso and elastic-net regularized generalized linear models. R Package Version 1.9–8. 2014. Available at: http://CRAN.R-project.org/package=glmnet. [Ref Type: Online Source].

19. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.

20. Schenper M. Cox analysis of survival data with non-proportional hazard functions. Statistician. 1992;41:455–65.

21. Ishwaran H, Kogalur U, Blackstone E, Lauer M. Random survival forests. Ann Appl Stat. 2008;2:841–60.

22. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005;365(9458):488–92.